IDEXX Laboratories, Inc. IDXX is set to release third-quarter 2026 results on Nov. 2, before the opening bell.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $4.27, which surpassed the Zacks Consensus Estimate by 8.10%. IDEXX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 5.74%.
IDEXX’s Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.19 billion, indicating an increase of 7.5% from the year-ago figure.
The Zacks Consensus Estimate for EPS is pinned at $3.71, implying a rise of 9.1% from the year-ago figure.
Estimate Revision Trend Ahead of IDEXX’s Q3 Earnings
Estimates for third-quarter earnings have remained unchanged in the past 60 days.
Here’s a brief snapshot of the pet healthcare innovator’s performance leading up to the announcement.
Key Drivers of IDEXX’s Q3 Performance
Companion Animal Group (“CAG”)
The business is likely to have sustained its momentum in the third quarter of 2026, supported by continued volume growth. CAG Diagnostics' recurring revenues are expected to have been a key driver of this performance, with robust gains across both the U.S. and international regions.
IDEXX VetLab consumables might have benefited from volume expansion driven by net new customer gains in the premium instrument installed base and expanded testing utilization. Global Reference Lab revenues are likely to have benefited from an expanding customer base and increased same-store utilization, as existing customers adopted a broader testing menu, such as IDEXX Cancer Dx. Global Rapid Assay revenues are expected to have improved as the impact of customers transitioning pancreatic lipase testing to the Catalyst instrument platform gradually subsides.
Within Veterinary Software, Services and Diagnostic Imaging Systems, recurring revenue growth was likely supported by expanding cloud-based PIMS recurring revenues and increased adoption of the newly launched DR50 Plus platform. Additionally, the September acquisition of CoVetAI Inc. is expected to strengthen IDEXX’s global software presence through integration with IDEXX VetConnect PLUS while addressing the needs of veterinary practice teams in markets not currently served by its practice management systems.
On the flip side, continued pressure on wellness visits might have remained a key constraint on clinical visit growth during the third quarter.
The Zacks Consensus Estimate for CAG’s third-quarter business revenues implies an increase of 7.9%.
Water
The segment’s revenues are expected to have benefited from both the United States and international regions, including benefits from order recovery in the Middle East.
The Zacks Consensus Estimate for Water’s revenues implies 6.4% year-over-year growth.
IDEXX Laboratories, Inc. Price and EPS Surprise
IDEXX Laboratories, Inc. price-eps-surprise | IDEXX Laboratories, Inc. Quote
Livestock, Poultry and Dairy (“LPD”)
Revenues in this division might have gained from an increase in test volumes across all regions.
The Zacks Consensus Estimate for LPD revenues indicates a 3.5% year-over-year increase.
What Our Model Says About IDXX
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is exactly the case here, as you can see below:
Earnings ESP: IDEXX Laboratories has an Earnings ESP of +0.59%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Top MedTech Picks
Here are some other medical stocks worth considering, as these too have the right combination of elements to post an earnings beat this time around:
TG Therapeutics TGTX has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon.
TGTX’s earnings beat estimates in one of the trailing four quarters and missed in the other three, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter’s figure.
Revvity RVTY has an Earnings ESP of +1.03% and a Zacks Rank #2 at present. The company is slated to release third-quarter 2026 results on Nov. 3.
RVTY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter’s figure.
Acadia Healthcare ACHC has an Earnings ESP of +4.84% and a Zacks Rank #3 at present. The company is slated to release third-quarter results on Nov. 4.
ACHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 47.02%. The Zacks Consensus Estimate for third-quarter EPS calls for a decrease of 36.1% from the year-ago quarter’s figure.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
Acadia Healthcare Company, Inc. (ACHC): Free Stock Analysis Report
TG Therapeutics, Inc. (TGTX): Free Stock Analysis Report
Revvity Inc. (RVTY): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).